Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.
Our objective was to perform a meta-analysis of randomized controlled trials of dopamine agonists (DA) as monotherapy as well as adjunctive therapy for the early treatment of Parkinson's disease (PD). A systematic literature search was conducted through April 2007. Both efficacy and safety endpoints were evaluated. DA monotherapy showed superior efficacy but more frequent adverse events compared to placebo. In addition, DA demonstrated inferior efficacy to levodopa, but was associated with fewer motor complications. However, DAs were associated with a greater incidence of nuisance side effects, such as hallucinations, somnolence and dizziness. The use of DA is an effective treatment option for the treatment of early PD and appears especially useful among PD patients with wearing-off phenomenon or dyskinesias on levodopa; however it may result in more adverse events and higher withdrawal rates.
Baker
William L
WL
School of Pharmacy, University of Connecticut, CT, USA.
Silver
Dee
D
White
C Michael
CM
Kluger
Jeffrey
J
Aberle
Jeffrey
J
Patel
Aarti A
AA
Coleman
Craig I
CI
D016206:Databases, Bibliographic / Q000706:statistics & numerical data; D018491:Dopamine Agonists / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
D018491:Dopamine Agonists; D007980:Levodopa